Neluos

Neluos may be available in the countries listed below.

Ingredient matches for Neluos

Oxybutynin

Oxybutynin hydrochloride (a derivative of Oxybutynin) is reported as an ingredient of Neluos in the following countries:

• Japan

International Drug Name Search

Alvesco

Alvesco is a brand name of ciclesonide, approved by the FDA in the following formulation(s):

ALVESCO (ciclesonide - aerosol, metered; inhalation)

• 
  Manufacturer: NYCOMED US
  
  Approval date: January 10, 2008
  
  Strength(s): 0.08MG/INH, 0.16MG/INH ^[RLD]

Has a generic version of Alvesco been approved?

No. There is currently no therapeutically equivalent version of Alvesco available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Alvesco. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Pregna-1,4-diene3,20-dione-16-17-acetal-21 esters, process for their preparation, composition, and methods for the treatment of inflammatory conditions
  Patent 5,482,934
  Issued: January 9, 1996
  Inventor(s): Calatayud; Jose & Conde; Jose R. & Luna; Manuel
  Assignee(s): Especialidades Latinas Medicamentos Universales, S.A. (Elmu, S.A.)
  The present invention relates to compounds of the formula: ##STR1## in which X.sub.1 and X.sub.2 correspond to H or F without distinction; R.sub.1 represents the following radicals: ##STR2## and R.sub.2 represents the radicals ##STR3## in the form of an R epimer, an S epimer, or a stereoisomeric mixture of the R and S epimers in terms of the orientation of the substituents on the carbon atom at position 22, novel intermediates and a method of their preparation by hydrolysis-ketalization, and use of such compounds as drugs and/or therapeutic agents.
  
  Patent expiration dates:
  
  
  • October 24, 2017
    
    ✓ 
    Patent use: METHOD OF TREATING INFLAMMATORY CONDITIONS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Medicinal aerosol formulations
  Patent 5,605,674
  Issued: February 25, 1997
  Inventor(s): Purewal; Tarlochan S. & Greenleaf; David J.
  Assignee(s): Riker Laboratories, Inc.
  A self-propelling aerosol formulation which may be free from CFC's which comprises a medicament, 1,1,1,2-tetrafluoroethane, a surface active agent and at least one compound having a higher polarity than 1,1,1,2-tetrafluoroethane.
  
  Patent expiration dates:
  
  
  • February 25, 2014
    
    ✓ 
    Drug product
  
  



• 
  Medicinal aerosol formulations
  Patent 5,683,677
  Issued: November 4, 1997
  Inventor(s): Purewal; Tarlochan S. & Greenleaf; David J.
  Assignee(s): Riker Laboratories, Inc.
  A self-propelling aerosol formulation which may be free from CFC's which comprises a medicament, 1,1,1,2-tetrafluoroethane, a surface active agent and at least one compound having a higher polarity than 1,1,1,2-tetrafluoroethane.
  
  Patent expiration dates:
  
  
  • November 4, 2014
    
    ✓ 
    Drug product
  
  



• 
  Seal configuration for aerosol canister
  Patent 5,775,321
  Issued: July 7, 1998
  Inventor(s): Alband; Todd D.
  Assignee(s): Minnesota Mining and Manufacturing Company
  A dual seal configuration for an aerosol canister containing a medicinal aerosol formulation. The canister includes a vial body and valve ferrule sealed by first and second sealing members to form a chamber that contains the medicinal aerosol formulation. The dual seal configuration reduces leakage of contents, and is particularly helpful where the formulation includes hydrofluorocarbon propellant and an ethanol cosolvent. The first seal can be selected to be a barrier to the formulation components, while the second seal can be relatively more labile to such components.
  
  Patent expiration dates:
  
  
  • July 7, 2015
    
    ✓ 
    Drug product
  
  



• 
  Device for delivering an aerosol
  Patent 6,006,745
  Issued: December 28, 1999
  Inventor(s): Marecki; Paul E.
  Assignee(s): Minnesota Mining and Manufacturing Company
  A device for delivering an aerosol comprises a casing member, a valve stem, and a sealing member, wherein the sealing member comprises a thermoplastic elastomer comprising of a copolymer of about 80-95 mole % ethylene and about 5-20 mole % of at least one comonomer wherein the comonomer(s) are 1-butene, 1-hexene, or 1-octene. The device is used with pharmaceutical formulations containing 1,1,1,2-tetrafluoroethane and/or 1,1,1,2,3,3,3-heptafluoropropane as the propellant.
  
  Patent expiration dates:
  
  
  • December 28, 2016
    
    ✓ 
    Drug product
  
  



• 
  Seal configuration for aerosol canister
  Patent 6,036,942
  Issued: March 14, 2000
  Inventor(s): Alband; Todd D.
  Assignee(s): 3M Innovative Properties Company
  An aerosol canister for containing a medicinal aerosol formulation. The canister involves a vial body and a valve ferrule sealed by first and second sealing members to form a chamber that contains the medicinal aerosol formulation.
  
  Patent expiration dates:
  
  
  • April 30, 2013
    
    ✓ 
    Drug product
  
  



• 
  Medicinal aerosol products containing formulations of ciclesonide and related steroids
  Patent 6,120,752
  Issued: September 19, 2000
  Inventor(s): Oliver; Martin J. & Fatania; Kanu M. & Scott; John S. & Muller; Helgert
  Assignee(s): 3M Innovative Properties Company
  Byk Gulden Lomberg Chemische Fabrik GmbH
  A pharmaceutical aerosol formulation suitable for oral and/or nasal inhalation including an anti-inflammatory steroid of the formula ##STR1## in which: R.sub.1 is 1-butyl, 2-butyl, cyclohexyl or phenyl and R.sub.2 is acetyl or isobutanoyl, in particular ciclesonide. The formulations also include hydrofluorocarbon propellants such as HFC 134a and/or 227, and cosolvent such as ethanol in an amount sufficient to solubilize the ciclesonide or related steroid (and various optional ingredients, such as surfactant). The formulations exhibit very desirable physical and chemical stability, as well as excellent delivery characteristics.
  
  Patent expiration dates:
  
  
  • May 13, 2018
    
    ✓ 
    Drug product
  
  



• 
  Medicinal aerosol formulation of ciclesonide and related compounds
  Patent 6,264,923
  Issued: July 24, 2001
  Inventor(s): Oliver; Martin J. & Fatania; Kanu M. & Scott; John S. & Muller; Helgert
  Assignee(s): 3M Innovative Properties Company
  A pharmaceutical aerosol formulation suitable for oral and/or nasal inhalation including an anti-inflammatory steroid of the formula ##STR1## in which: R.sub.1 is 1-butyl, 2-butyl, cyclohexyl or phenyl and R.sub.2 is acetyl or isobutanoyl, in particular ciclesonide. The formulations also include hydrofluorocarbon propellants such as HFC 134a and/or 227, and cosolvent such as ethanol in an amount sufficient to solubilize the ciclesonide or related steroid (and various optional ingredients, such as surfactant). The formulations exhibit very desirable physical and chemical stability, as well as excellent delivery characteristics.
  
  Patent expiration dates:
  
  
  • May 13, 2018
    
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • January 10, 2011 - NEW DOSAGE FORM
  
  
  • October 20, 2011 - NEW CHEMICAL ENTITY
  
  

See also...

• Alvesco Consumer Information (Drugs.com)
• Alvesco Aerosol Consumer Information (Wolters Kluwer)
• Alvesco HFA inhalation Consumer Information (Cerner Multum)
• Alvesco inhalation Consumer Information (Cerner Multum)
• Alvesco Advanced Consumer Information (Micromedex)
• Ciclesonide Aerosol Consumer Information (Wolters Kluwer)
• Ciclesonide inhalation Consumer Information (Cerner Multum)
• Ciclesonide Inhalation Advanced Consumer Information (Micromedex)

Defencare

Defencare may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Defencare

Permethrin

Permethrin is reported as an ingredient of Defencare in the following countries:

• Germany


• Netherlands


• United Kingdom

International Drug Name Search

Selsun Gold

Ingredient matches for Selsun Gold

Selenium Sulfide

Selenium Sulfide is reported as an ingredient of Selsun Gold in the following countries:

• United States

International Drug Name Search

Humalog Mix 75 / 25

See also: Generic Humalog Mix 50/50, Generic Humalog Mix 50/50 KwikPen, Generic Humalog Mix 50/50 Pen, Generic Humalog Mix 75/25 KwikPen, Generic Humalog Mix 75/25 Pen

Humalog Mix 75/25 is a brand name of insulin lispro/insulin lispro protamine, approved by the FDA in the following formulation(s):

HUMALOG MIX 75/25 (insulin lispro protamine recombinant; insulin lispro recombinant - injectable; injection)

• 
  Manufacturer: LILLY
  
  Approval date: December 22, 1999
  
  Strength(s): 75 UNITS/ML;25 UNITS/ML ^[RLD]

Has a generic version of Humalog Mix 75/25 been approved?

No. There is currently no therapeutically equivalent version of Humalog Mix 75/25 available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Humalog Mix 75/25. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Monomeric insulin analog formulations
  Patent 5,461,031
  Issued: October 24, 1995
  Inventor(s): De Felippis; Michael R.
  Assignee(s): Eli Lilly and Company
  The present invention discloses various parenteral pharmaceutical formulations, which comprise: a monomeric insulin analog, zinc, protamine, and phenolic derivative. The analog formulations provide a prolonged duration of action. A process for preparing insulin analog-protamine formulations is also described.
  
  Patent expiration dates:
  
  
  • June 16, 2014
    
  
  



• 
  Insulin analog formulations
  Patent 5,474,978
  Issued: December 12, 1995
  Inventor(s): Bakaysa; Diane L. & Brems; David N. & Frank; Bruce H. & Havel; Henry A. & Pekar; Allen H.
  Assignee(s): Eli Lilly and Company
  The present invention discloses a human insulin analog hexamer complex and formulations. More specifically, the present invention relates to various parenteral formulations, which comprise: human insulin analogs in a hexamer conformation, zinc ions, and at least three molecules of a phenolic derivative selected from the group consisting of m-cresol, phenol, or a mixture of m-cresol and phenol. The formulation provides a rapid onset of action.
  
  Patent expiration dates:
  
  
  • June 16, 2014
    
  
  



• 
  Insulin analogs modified at position 29 of the B chain
  Patent 5,514,646
  Issued: May 7, 1996
  Inventor(s): Chance; Ronald E. & DiMarchi; Richard D. & Frank; Bruce H. & Shields; James E.
  Analogs of human insulin modified at position 29 of the B chain thereof and, optionally, at other positions, have modified physico-chemical and pharmacokinetic properties and are useful in the treatment of hyperglycemia.
  
  Patent expiration dates:
  
  
  • May 7, 2013
    
  
  



• 
  Monomeric insulin analog formulations
  Patent 5,747,642
  Issued: May 5, 1998
  Inventor(s): De Felippis; Michael R.
  Assignee(s): Eli Lilly and Company
  The present invention discloses various parenteral pharmaceutical formulations, which comprise: a monomeric insulin analog, zinc, protamine, and phenolic derivative. The analog formulations provide a prolonged duration of action. A process for preparing insulin analog-protamine formulations is also described.
  
  Patent expiration dates:
  
  
  • June 16, 2014
    
  
  

See also...

• HumaLog Mix 75/25 Vials Consumer Information (Wolters Kluwer)
• Humalog Mix 75/25 Pens Consumer Information (Wolters Kluwer)
• Humalog Mix 75/25 Consumer Information (Cerner Multum)
• Humalog Mix 75/25 Advanced Consumer Information (Micromedex)
• Humalog Mix Consumer Information (Drugs.com)
• Insulin Lispro Protamine/Insulin Lispro Pens Consumer Information (Wolters Kluwer)
• Insulin Lispro Protamine/Insulin Lispro Vials Consumer Information (Wolters Kluwer)
• Insulin lispro and insulin lispro protamine Consumer Information (Cerner Multum)
• Insulin lispro protamine and insulin lispro Subcutaneous Advanced Consumer Information (Micromedex)

EnaLich comp

EnaLich comp may be available in the countries listed below.

Ingredient matches for EnaLich comp

Enalapril

Enalapril maleate (a derivative of Enalapril) is reported as an ingredient of EnaLich comp in the following countries:

• Germany

Hydrochlorothiazide

Hydrochlorothiazide is reported as an ingredient of EnaLich comp in the following countries:

• Germany

International Drug Name Search

Ketotifen

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

R06AX17,S01GX08

CAS registry number (Chemical Abstracts Service)

0034580-13-7

Chemical Formula

C19-H19-N-O-S

Molecular Weight

309

Therapeutic Categories

Antiasthmatic agent

Antiallergic agent

Histamine, H₁-receptor antagonist

Chemical Name

10H-Benzo[4,5]cyclohepta[1,2-b]thiophen-10-one, 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-

Foreign Names

• Ketotifenum (Latin)
• Ketotifen (German)
• Kétotifène (French)
• Ketotifeno (Spanish)

Generic Names

• Ketotifen (OS: BAN)
• Ketotifene (OS: DCIT)
• Kétotifène (OS: DCF)
• Ketotifen Fumarate (OS: USAN, JAN, BANM)
• HC 20 511 nfu (IS)
• HC 20-511 (IS)
• Ketotifenhydrogenfumarat (IS)
• Ketotifen Fumarate (PH: BP 2010)
• Ketotifen Hydrogen Fumarate (PH: Ph. Eur. 6)
• Ketotifeni hydrogenfumaras (PH: Ph. Eur. 6)

Brand Names

• Alaway
  Bausch & Lomb, United States



• Alerfast
  Aversi, Georgia



• Astafen
  Sandoz, Turkey



• Asthafen
  Torrent, India; Torrent, Myanmar



• Blasket
  Blaskov, Colombia



• Cosolve
  Vargas, Venezuela



• Dhatifen
  DHA, Singapore



• Difen
  Biogen, Colombia



• Dihalar
  Krka, Slovenia



• Frenasma
  Faran, Romania



• Galitifen
  Galenika, Serbia



• Histofen
  Riyad Pharma, Oman; Riyadh, Bahrain



• K-Asmal
  Silanes, Guatemala; Silanes, Nicaragua



• K-Drops
  Alapis Pharma, Greece



• Ketifen
  Farqui, Dominican Republic



• Ketin
  Opalia, Tunisia



• Ketobron
  Farmacoop, Colombia



• Ketonil
  Ram Pharmaceutical, Oman; Roemmers, Peru



• Ketotifen Actavis
  Actavis, Lithuania



• Ketotifen Help
  Help, Greece



• Ketotifen LPH
  Labormed Pharma, Romania



• Ketotifen
  Actavis, Georgia; GMP, Georgia; Hasco, Poland; Polfa Warszawa, Lithuania



• Ketotifeno Ecar
  Ecar, Colombia



• Ketotifeno Farmindustria
  Farmindustria, Peru



• Ketotifeno Genfar
  Genfar, Colombia; Genfar, Ecuador; Genfar, Peru



• Ketotifeno La Santé
  La Sante, Peru; La Santé, Colombia



• Ketotifeno MK
  McKesson, Ecuador; MK, Colombia



• Ketotifeno Terbol
  Terbol, Peru



• Ketotifeno
  AZ Pharma, Colombia; Medicalex, Colombia; Pentacoop, Colombia; Synthesis, Colombia



• Ketotiphen
  BHFZ, Georgia



• Ketotisin
  Chemopharma, Chile; Dollder, Venezuela



• Loristat
  Farmacoop, Colombia



• Oftaler
  Saval Nicolich, Chile



• Tefanyl
  Saiph, Tunisia; Simed, Tunisia



• Totinal
  Hikma, United Arab Emirates; Hikma, Bahrain; Hikma, Egypt; Hikma, Iraq; Hikma, Jordan; Hikma, Kuwait; Hikma, Lebanon; Hikma, Libya; Hikma, Oman; Hikma, Qatar; Hikma, Saudi Arabia; Hikma, Sudan; Hikma, Syria; Hikma, Yemen



• Zaditen Oft.
  Novartis Ophthalmics, Peru



• Zaditen
  Adcock Ingram Pharmaceuticals, South Africa; Defiante, Luxembourg; Novartis, Taiwan; Novartis, Yemen



• Zasten
  Novartis, Spain



• Adco-Ketotifen
  Adcock Ingram Pharmaceuticals, South Africa



• Adco-Zetofen
  Adcock Ingram Pharmaceuticals, South Africa



• Aerofen
  Silva, Bangladesh



• Alarid
  Square, Bangladesh



• Alaway
  Bausch & Lomb, United States



• Allerket
  Pulitzer, Italy



• Amitone
  Unison, Sri Lanka; Unison, Singapore



• Anatifen
  Kobayashi Kako, Japan



• Antilerg
  Valeant, Argentina



• Apo-Ketotifen
  Apotex, Guyana



• Asdron
  Marjan, Brazil



• Asmafen
  Pan Pharma, Sri Lanka; Xepa-Soul Pattinson, Hong Kong



• Asmafort
  Julphar, Bahrain; Julphar, Oman



• Asmalergin
  Merck, Brazil



• Asmen
  Farmalab, Brazil



• Astifen
  Kalbe Farma, Sri Lanka



• Asumalife
  Yung Shin, Singapore



• Beatifen
  Beacons, Singapore



• Benanza
  Isei, Japan



• Benapy
  Sandoz, Japan



• Bentifen
  Novartis, Italy



• Bilozen
  Klonal, Argentina



• Broncoten
  Farmion, Brazil



• Butifeno
  Bruluart, Mexico



• Chetofen
  B&G, Italy



• Chetotifene Mylan
  Mylan, Italy



• Cipanfeno
  Cipan, Portugal



• Cratifen
  Kyowa Yakuhin, Japan



• Denerel
  Medochemie, Bangladesh; Medochemie, Slovakia; Medochemie, Taiwan



• Dezuwart
  Yoshindo, Japan



• Dihalar
  Krka, Croatia (Hrvatska)



• Dovidin
  Anfarm, Greece



• Drakern
  Nichi-Iko PharmaceuticalJMA, Japan



• Ecradin
  Med-One, Greece



• Electer
  Mylan Pharmaceutical, Japan



• Erliten
  Malaysia Chemist, Singapore



• Eucycline
  Demo, Greece



• Fenat
  Drug International, Bangladesh



• Fental Nexus
  Nexus Medicals, Greece



• Frenasma
  Faran Laboratories, Greece



• Fumarton
  Nippon Tenganyaku KenkyujoNitten, Japan



• Fumarufen
  Nichi-Iko PharmaceuticalJMA, Japan



• Fusachol
  Medisa Shinyaku, Japan



• Gloditen
  Global Pharma, Bahrain; Global Pharma, Oman



• H-Ketotifen
  Helcor, Romania



• Hyalcrom
  Bausch & Lomb, Argentina



• Intifen
  Interbat, Indonesia



• Isocaren
  Pharmanel, Greece



• Kathricol
  Mediapharm, Greece



• Kedrop
  Grin, Mexico



• Kenaler BPL
  BPL, Peru



• Kenaler
  Ophtha, Colombia



• Ketasma
  Sun, Bangladesh; Sun, India; Sun, Sri Lanka; Sun, Myanmar



• Ketifen
  Acme, Bangladesh



• Ketocev
  Cevallos, Argentina



• Ketodil
  Techno, Bangladesh



• Ketof
  Hexal, Czech Republic; Hexal, Germany; Hexal, Luxembourg; Hexal, Romania; IBN, Myanmar; Ibn Sina, Bangladesh



• Ketofen
  Tabuk, Bahrain; Tabuk Pharmaceutical, Oman



• Ketoftil
  Farmigea, Italy; Farmigea, Malta



• Ketomar
  Incepta, Bangladesh



• Ketoptic
  Oftalmi, Venezuela



• Ketoten
  Sawai Seiyaku, Japan



• Ketotif
  Delta, Bangladesh



• Ketotifen Actavis
  Actavis, Latvia; Actavis, Netherlands; Balkanpharma, Bulgaria



• Ketotifen AL
  Aliud, Czech Republic



• Ketotifen CF
  Centrafarm, Netherlands



• Ketotifen Fumarate
  Akorn, United States; Alcon, United States; Apotex, United States



• Ketotifen PCH
  Pharmachemie, Netherlands



• Ketotifen Ratiopharm
  ratiopharm, Netherlands



• Ketotifen Sandoz
  Sandoz, Netherlands



• Ketotifen Sopharma
  Sopharma, Bulgaria



• Ketotifen Stada
  Stada, Germany



• Ketotifen Teva
  Teva, Belgium



• Ketotifen WZF Polfa
  WZF Polfa, Slovakia



• Ketotifen
  Briz, Latvia; Magistra, Romania; Polfa Warszawa, Georgia; Polfa Warszawa, Poland; Sopharma, Georgia; Sopharma, Russian Federation; Toa Yakuhin, Japan



• Ketotifeno MK
  Bonima, Costa Rica



• Ketotilon
  Ohara Yakuhin, Japan



• Ketotisan
  Wabosan, Austria



• Klevistamin
  Kleva, Greece



• Kofen
  Opsonin, Bangladesh



• Labelphen
  Chrispa, Greece



• Licoften
  Remedica, Bahrain; Remedica, Cyprus; Remedica, Oman



• Magotiphen
  Tsuruhara Seiyaku, Japan



• Mellabon
  Taiyo Pharmaceutical, Japan



• Meni-Drops
  Pharmex, Greece



• Minia
  Novo Healthcare, Bangladesh



• Nichicard
  Nisshin Seiyaku - Yamagata, Japan



• Nortifen
  Otto, Indonesia



• Noxtor
  Rafarm, Greece



• Orpidix
  Proel, Greece



• Pädiatifen
  Pädia, Germany



• Pellexeme
  Coup, Greece



• Profilar
  United Pharmaceutical, United Arab Emirates; United Pharmaceutical, Bahrain; United Pharmaceutical, Iraq; United Pharmaceutical, Jordan; United Pharmaceutical, Libya; United Pharmaceutical, Oman; United Pharmaceutical, Qatar; United Pharmaceutical, Saudi Arabia; United Pharmaceutical, Sudan; United Pharmaceutical, Yemen



• Profilas
  Dankos Laboratories, Indonesia



• Profiten
  Pharma Clal, Israel



• Prosma
  ACI, Bangladesh



• Respimex
  Pfizer, Argentina



• Sadifen
  Daito, Japan



• Salatine
  Nipro PharmaNipurofama, Japan



• Saldimen
  Tatsumi Kagaku, Japan



• Scanditen
  Tempo Scan Pacific, Indonesia



• Sekiton
  Kyorin Rimedio, Japan



• Sosefen
  So.Se., Italy



• Stafen
  Aristopharma, Bangladesh



• Stamifen
  Pliva, Italy



• Supdel
  Towa Yakuhin, Japan



• Tenerel
  Medochemie, Bahrain; Medochemie, Cyprus; Medochemie, Iraq; Medochemie, Jordan; Medochemie, Sudan; Medochemie, Tanzania; Medochemie, Yemen



• Tifen
  Pharmalliance, Algeria; Somatec, Bangladesh



• Tofen
  Beximco, Bangladesh



• Toma
  Navana, Bangladesh



• Toti
  Eskayef, Bangladesh



• Totifen
  Elpen, Greece



• Zadec
  Novartis, Philippines



• Zaditen
  Novartis, United Arab Emirates; Novartis, Argentina; Novartis, Austria; Novartis, Australia; Novartis, Belgium; Novartis, Bahrain; Novartis, Brazil; Novartis, Switzerland; Novartis, Chile; Novartis, Colombia; Novartis, Czech Republic; Novartis, Germany; Novartis, Denmark; Novartis, Ecuador; Novartis, Egypt; Novartis, Spain; Novartis, Finland; Novartis, France; Novartis, United Kingdom; Novartis, Ghana; Novartis, Greece; Novartis, Guyana; Novartis, Hong Kong; Novartis, Croatia (Hrvatska); Novartis, Indonesia; Novartis, Ireland; Novartis, Israel; Novartis, Iraq; Novartis, Iran; Novartis, Iceland; Novartis, Italy; Novartis, Jordan; Novartis, Japan; Novartis, Kenya; Novartis, Kuwait; Novartis, Lebanon; Novartis, Lithuania; Novartis, Luxembourg; Novartis, Latvia; Novartis, Libya; Novartis, Malta; Novartis, Mexico; Novartis, Malaysia; Novartis, Nigeria; Novartis, Netherlands; Novartis, Norway; Novartis, New Zealand; Novartis, Oman; Novartis, Philippines; Novartis, Poland; Novartis, Portugal; Novartis, Qatar; Novartis, Romania; Novartis, Russian Federation; Novartis, Saudi Arabia; Novartis, Sudan; Novartis, Singapore; Novartis, Syria; Novartis, Thailand; Novartis, Turkey; Novartis, Tanzania; Novartis, Venezuela; Novartis, South Africa; Novartis, Zimbabwe; Novartis Healthcare, Sweden; Novartis Ophthalmics, Hungary; Novartis Ophthalmics, Singapore; Novo Nordisk, Slovenia; Paladin, Canada; Sigma-tau, Germany; Zentiva, Slovakia



• Zaditen SRO
  Defiante, Austria



• Zaditoma
  Kyowa Yakuhin, Japan



• Zaditor
  Novartis, Canada; Novartis, United States



• Zaltifen
  Choseido Pharmaceutical, Japan



• Zatin
  Shiba, Yemen



• Zatotiten
  Kotobuki Seiyaku, Japan



• Zetitec
  UCI, Brazil



• Zikilion
  Nichi-Iko PharmaceuticalJMA, Japan

International Drug Name Search

Glossary

BAN	British Approved Name
BANM	British Approved Name (Modified)
DCF	Dénomination Commune Française
DCIT	Denominazione Comune Italiana
IS	Inofficial Synonym
JAN	Japanese Accepted Name
OS	Official Synonym
PH	Pharmacopoeia Name
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.